

Aetiology of Lobar Pneumonia Determined by Multiplex Molecular Analyses of Lung and Pleural Aspirate Specimens in The Gambia

Grant A Mackenzie^{1,2,3,4} PhD, Jessica McLellan^{1,5} PhD, Eunice Machuka¹ MSc, Malick Ndiaye¹ DP, Jayani Pathirana¹ PhD, Augustin Fombah¹ MD, Baderinwa Abatan¹ FWACP, Ilias Hossain¹ MPH, Ahmed Manjang¹ MSc, Brian Greenwood³ MD, Philip C Hill⁴ MD

1. Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia, West Africa
2. Infection and Immunity Theme, Murdoch Children's Research Institute, Melbourne, Australia
3. Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK
4. Department of Paediatrics, University of Melbourne, Melbourne, Australia
5. Cumming School of Medicine, University of Calgary, Calgary, Canada
6. Centre for International Health, University of Otago, Dunedin, New Zealand

Keywords: Pneumonia; Aetiology; Lung Aspirate; Co-infection; Polymerase-chain-reaction; Gambia

Corresponding author: Dr Grant A Mackenzie, MRC Unit The Gambia at London School of Hygiene &

Tropical Medicine, PO Box 273 Banjul, The Gambia, West Africa; ph. +220 7207826, email.

gmackenzie@mrc.gm

Word count abstract – 250

Word count text – 2934

25 **Abstract**

26 **Background**

27 Pneumonia aetiology generally relies on insensitive blood cultures or an assumption that organisms in the
28 pharynx are causal. We determined the causes of lobar pneumonia in rural Gambia using lung aspiration.

29 **Methods**

30 Pneumonia surveillance was undertaken among all ages. Blood culture and chest radiographs were
31 performed routinely while lung or pleural aspirates were collected from selected patients. 7-valent
32 pneumococcal conjugate vaccine (PCV7) was introduced in August 2009 and replaced by PCV13 from May
33 2011. We used conventional microbiology, and from April 8, 2011 to July 17, 2012, utilized a multiplex PCR
34 assay on lung aspirates. We calculated proportions with pathogens, associations between co-infecting
35 pathogens, and PCV effectiveness.

36 **Results**

37 2,550 patients were admitted with clinical pneumonia; 741 with lobar pneumonia or pleural effusion. We
38 performed multiplex PCR on 156 lung and 4 pleural aspirates. Pathogens were detected in 116 specimens,
39 *Streptococcus pneumoniae* (n=68), *Staphylococcus aureus* (n=26), and *Haemophilus influenzae* type b
40 (n=11). Bacteria (n=97) were more common than viruses (n=49). Common viruses were bocavirus (n=11)
41 and influenza (n=11). Co-infections were frequent (n=55). *M. catarrhalis* was detected in eight patients and
42 in every case there was co-infection with *S. pneumoniae*. The odds ratio of vaccine-type pneumococcal
43 pneumonia in patients with two or three compared to zero doses of PCV was 0.17 (95% CI 0.06, 0.51).

44 **Conclusions**

45 Lobar pneumonia in rural Gambia was caused primarily by bacteria, particularly *S. pneumoniae* and *S.*
46 *aureus*. Co-infection was common and *M. catarrhalis* always co-infected with *S. pneumoniae*. PCV was
47 highly efficacious against vaccine-type pneumococcal pneumonia.

48

49

50

51

52 **Key Messages**

53 What is the key question?

54 Using specimens directly from the infected lung, what is the aetiology of lobar pneumonia in rural West

55 Africa?

56

57 What is the bottom line?

58 Using specimens directly from the infected lung, *Streptococcus pneumoniae* and *Staphylococcus aureus*

59 were the predominant causes of lobar pneumonia in rural West Africa and pneumococcal conjugate

60 vaccine effectively prevented pneumococcal pneumonia.

61

62 Why read on?

63 Learn about the certain aetiology of lobar pneumonia in 160 Gambian patients with specimens directly

64 from the lung.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79 **INTRODUCTION**

80 Most studies of the aetiology of pneumonia rely on either the insensitive culture of bacteria from blood or
81 the non-specific detection of organisms in sputum or pharynx. Case-control studies have compared the
82 prevalence of organisms in the pharynx of children with pneumonia and matched controls, relying on the
83 assumption that organisms detected in the pharynx are also present and pathogenic in the lung.¹⁻⁴ The
84 multi-site Pneumonia Etiology for Research in Child Health (PERCH) study extended these methods,
85 combining conventional and molecular microbiology data from the pharynx, blood, and lung with an
86 analytic approach to estimate the probability of specific aetiologies.²

87

88 Historic studies using lung aspirate specimens and conventional microbiology commonly found *S.*
89 *pneumoniae* and *H. influenzae* to be the most frequent causes of lobar pneumonia.⁵⁻⁸ More recent studies
90 using lung aspirates have been uncommon. A Gambian study employing molecular methods in 47 lung and
91 nine pleural aspirates, and the PERCH study with 37 lung and 15 pleural aspirates, identified a
92 pneumococcal aetiology in 87% and 25% of patients respectively.^{2,9} Co-infection was present in 51%⁹ and
93 17% of patients respectively.^{2,9} The PERCH study may have underestimated the prevalence of bacterial
94 infection in pneumonia due to the inclusion of children with bronchiolitis, challenges enrolling very sick
95 children, and an assumption that organisms in pharyngeal specimens correlate with the cause of
96 pneumonia.¹⁰

97

98 The importance of determining the aetiology of pneumonia, particularly the role of co-infections and the
99 impact of vaccination strategies, remains. We studied these questions in rural Gambia during the
100 introduction of pneumococcal conjugate vaccination (PCV), applying conventional and molecular methods
101 to lung specimens.

102

103 **METHODS**

104 **Setting**

105 This study was nested within a surveillance study for suspected pneumonia, septicaemia, or meningitis in
106 the Basse and Fuladu West Health and Demographic Surveillance Systems (BHDSS and FWHDSS) in rural
107 Gambia, which in January 2012, included approximately 170 043 and 89 389 residents respectively. Child
108 mortality in the BHDSS in 2011 was 68 per 1000 live births. Surveillance commenced in the BHDSS on May
109 12, 2008 and in the FWHDSS on September 12, 2011. PCV7 was introduced on August 19, 2009 and
110 replaced by PCV13 during May 2011.

111

112 **Patients and procedures**

113 The surveillance has been described previously.¹¹ Standardized methods were used for detection of
114 possible cases of pneumonia, septicaemia, meningitis, referral and clinical investigation.^{12,13} Suspected
115 pneumonia was defined as a history of cough or difficulty breathing with the presence of any one of the
116 following: respiratory rate ≥ 40 or ≥ 50 per minute for children aged greater than or less than 12 months
117 respectively, lower-chest-wall-indenting, nasal flaring, grunting, oxygen saturation $< 92\%$, dullness to
118 percussion, bronchial breathing or crackles on auscultation. Patients with suspected pneumonia had
119 anthropometric measurements, peripheral oxygen saturation measured, blood cultured, and chest
120 radiographs done. We did not test for HIV as this was not standard practice and prevalence in The Gambia
121 is relatively low.¹⁴ Chest radiographs were interpreted according to WHO recommendations¹⁵ by two
122 independent reviewers, with readings discordant for end-point consolidation (i.e. lobar pneumonia)
123 resolved by a third reviewer. A percutaneous trans-thoracic lung or pleural fluid aspiration was considered
124 if a pleural effusion or large, dense, peripheral pneumonic consolidation was present on radiograph, there
125 were no contraindications, and the patient was clinically stable. Following written, informed consent, lung
126 aspiration was performed by a clinician using aseptic technique with a 21 gauge needle, the sample diluted
127 in 1 ml of sterile saline with an aliquot inoculated on culture media. Patients were observed for 4 hours
128 post-procedure. Lung aspiration is established as a safe practice in The Gambia, with an excellent safety
129 record and sensitivity as a diagnostic tool.¹⁶ All patients admitted with clinical pneumonia from April 8,

130 2011 to July 17, 2012 were included in this study. We chose this period as it covered introduction period of
131 PCV.

132

133 **Laboratory procedures**

134 Microbiological specimens were processed in Basse using conventional microbiological methods including
135 staining of lung and pleural aspirates for *M. tuberculosis*.¹⁷ Blood was cultured using an automated system
136 (Bactec 9050, Beckton Dickinson, Belgium). We serotyped *S. pneumoniae* isolates by latex agglutination
137 using factor and group-specific antisera (Statens Serum Institute, Copenhagen, Denmark).¹⁸ *H. influenzae*
138 isolates were serotyped by slide agglutination using polyvalent and monovalent antisera to types a, b, c, d,
139 e and f (Beckton Dickinson, Erembodegem, Belgium). Isolates that did not agglutinate with polyvalent
140 antisera were classified as non-typeable *H. influenzae*.

141

142 Total nucleic acid was extracted from a 200µl aliquot of lung and pleural aspirates (easyMAG, bioMérieux,
143 France) with an internal control. Extracts were subjected to quantitative multiplex PCR (Fast-track
144 Diagnostics Resp-33 kit, Sliema, Malta) for a panel of 33 respiratory bacteria, fungi, and viruses (see
145 Supplementary Material) with internal positive, and negative controls.¹⁹ Standard PCR curves were derived
146 from plasmid standards during the testing to calculate pathogen load from cycle threshold values. We did
147 not use a density threshold to define a positive result based on the assumption that any putative pathogen
148 detected in consolidated lung or pleural fluid is pathogenic and involved in the pneumonic process.
149 Interpretation for some targets required combinations of results (see Supplementary Material). Assay
150 specificity for the *Klebsiella pneumoniae* and *Legionella* sp. targets was poor and therefore results for these
151 bacteria were omitted from analyses.

152

153 **Statistical analysis**

154 We summarised the characteristics of patients admitted with clinical pneumonia and classified them into
155 three groups; no radiological lobar consolidation and lobar consolidation with or without lung or pleural
156 aspirate. Categorical variables were assessed using chi-square tests and the Kruskal-Wallis test was used for

157 continuous variables. We calculated age-stratified proportions of patients with pathogens identified in lung
158 or pleural aspirates using multiplex PCR. Values of pathogen quantity were transformed to \log_{10} copies per
159 ml. We tabulated the frequency of co-infection by pairs of pathogens. We used test-negative analyses to
160 estimate the effectiveness of PCV to prevent pneumococcal pneumonia and vaccine-type pneumococcal
161 pneumonia; combining conventional culture and serotype results with PCR results as appropriate. We
162 calculated the odds of a positive versus negative test for the outcome in patients who had received ≥ 2
163 doses of PCV compared to zero doses seven or more days before admission. We calculated odds ratios and
164 95% confidence intervals in crude and age-stratified analyses using the Mantel-Haenszel method. Fisher's
165 exact p -values were used for hypothesis tests. Analyses were done using STATA version 16 (StataCorp,
166 College Station, USA).

167

168 **Ethical considerations**

169 Ethical approval was granted for the study by the Gambia Government/Medical Research Council (UK) Joint
170 Ethics Committee (numbers 1087 and 1247). Written informed consent was obtained from patients or
171 guardian for all study procedures.

172

173 **RESULTS**

174 Over the 21 month study period, 2550 patients were hospitalized with clinical pneumonia; 2406 were aged
 175 0-59 months and 141 were aged ≥ 5 years (figure 1). WHO-defined radiological pneumonia with
 176 consolidation (i.e. lobar pneumonia) was detected in 741 (29%) patients. Of those with lobar pneumonia,
 177 lung or pleural aspirates were collected from 176 and five (24%, 181/741) patients respectively. There were
 178 no complications following the lung aspiration procedures. Patients with lobar pneumonia aged 0-60 days
 179 were less likely than older patients to have a lung aspirate (1/64 versus 180/681) while older children and
 180 adults were more likely to have a lung aspirate than children aged 2-59 months (44/89 versus 136/592)
 181 [table 1]. Bacteremia was more common in patients who had a lung aspirate (31/178, 17%) compared to
 182 those without a lung aspirate (113/2119, 5%).

183

184 **Table 1. Characteristics of 2,550 patients admitted to hospital with clinical pneumonia, radiological**
 185 **findings and investigation with lung or pleural aspiration**

| Characteristic | Sub-group | No lobar consolidation (N=1,646) | Lobar consolidation no lung/pleural aspirate (N=564) | Lobar consolidation & lung/pleural aspirate (N=181) |
|--|--------------|----------------------------------|--|---|
| Age | 0-60 dy | 143 (8.7%) | 63 (11.2%) | 1 (0.5%) |
| | 2-59 mo | 1,452 (88.2%) | 456 (80.9%) | 136 (75.1%) |
| | 5-14 yr | 42 (2.6%) | 23 (4.1%) | 26 (14.4%) |
| | ≥ 15 yr | 9 (0.5%) | 22 (3.9%) | 18 (9.9%) |
| Male | | 933 (56.7%) | 324 (57.4%) | 104 (57.5%) |
| ^a Mean respiratory rate/min | | 57.3 | 61.6 | 60.8 |
| ^a Mean oxygen saturation % | | 95.8% | 93.6% | 95.1% |
| ^a Wheeze | | 319/1,641 (19.4%) | 76/562 (13.5%) | 11/181 (6.1%) |
| ^b Tachycardia | | 963 (58.5%) | 351 (62.2%) | 138 (76.2%) |
| ^a Temperature $\geq 38.0^\circ\text{C}$ | | 823 (50.0%) | 347 (61.5%) | 126 (69.6%) |
| ^a ^c Prostration | 0-59 mo | 116/1,572 (7.4%) | 34/513 (6.6%) | 5/136 (3.7%) |
| ^a ^d WfH z-score <-3 | 0-59 mo | 274/1,587 (17.3%) | 95/513 (18.5%) | 28/136 (20.6%) |
| ^e BMI grade 3 thinness | 5-17 yr | 9/44 (20%) | 8/28 (29%) | 8/28 (29%) |
| ^e BMI <18.5 | ≥ 18 yr | 1/7 (14%) | 4/16 (25%) | 3/15 (20%) |
| Blood culture taken | | 1,584 (96.2%) | 535 (94.9%) | 178 (98.3%) |

| | | | | |
|---------------------------------|---|-------------------|-----------------|----------------|
| Blood culture pathogen isolated | | 82/1,584 (5.2%) | 31/535 (5.8%) | 31/178 (17.4%) |
| | 0 | 357/1,452 (24.6%) | 109/456 (23.9%) | 43/136 (31.6%) |
| fPCV immunisation doses | 1 | 159/1,452 (11.0%) | 38/456 (8.3%) | 12/136 (8.8%) |
| | 2 | 152/1,452 (10.5%) | 50/456 (11.0%) | 10/136 (7.4%) |
| | 3 | 784/1,452 (54.0%) | 259/456 (56.8%) | 71/136 (52.2%) |
| Died in hospital | | 65 (3.9%) | 25 (4.4%) | 6 (3.3%) |

186 Note: Column totals do not equal 2,550 as 159 patients did not have a chest radiograph.

187 ^aMissing values: respiratory rate (n=1), oxygen saturation (n=5), wheeze (n=7), temperature (n=1), weight
188 (n=5), height (n=14), prostration (n=30).

189 ^bTachycardia defined as heart rate at admission >160 bpm in infants 0-11 months, >150 bpm in children 12-
190 23 months, >140 bpm in children 2-4 years, and >100 bpm in those aged ≥5 years.

191 ^cProstration defined as inability to sit if usually able or inability to feed.

192 ^dWfH – weight for height.

193 ^eBMI – body mass index.

194 ^fPCV doses if age 2-59 months; PCV7 only (no consolidation [n=441], consolidation no LA/PA [n=156],
195 consolidation LA/PA [n=58]), PCV13 only (no consolidation [n=300], consolidation no LA/PA [n=88],
196 consolidation LA/PA [n=6]), PCV7 and PCV13 (no consolidation [n=195], consolidation no LA/PA [n=65],
197 consolidation LA/PA [n=17]).

198

199

200

201 Multiplex PCR was performed on 160/181 lung and pleural aspirates. Twenty-one collected specimens were
202 not stored or available for PCR analysis. Before the exclusion of *K. pneumoniae* and *Legionella* results due
203 to poor specificity, at least one pathogen was detected in 132/160 patients, and after their exclusion,
204 pathogens were detected in 116/160 (73%) lung specimens (lung and pleural aspirates combined), one
205 pathogen in 61 (38%) and two or more in 55 (34%) [table 2]. Bacteria were detected in 97 (61%) specimens
206 and viruses in 49 (31%). Bacteria only infections were detected in 67 (42%) and bacterial co-infections in 26
207 (16%) specimens. Viral only infections were detected in 18 (11%) specimens with bacterial-viral co-
208 infections in 30 (19%).

209

210 **Table 2. Organisms identified by multiplex PCR assay in patients with lung (n=156) and pleural (n=4)**
 211 **aspirate specimens**

| Specific pathogens isolated | 0-23 mo (N=77) | 2-4 yr (N=43) | ≥5 yr (N=40) | All ages (N=160) |
|--|-----------------------|----------------------|---------------------|-------------------------|
| | n (%) | n (%) | n (%) | n (%) |
| <i>Streptococcus pneumoniae</i> | 26 (34) | 22 (51) | 20 (50) | 68 (42.5) |
| <i>Staphylococcus aureus</i> | 15 (19) | 7 (16) | 4 (10) | 26 (16.3) |
| <i>Haemophilus influenzae</i> type b | 6 (8) | 5 (12) | 0 (0) | 11 (6.9) |
| <i>Pneumocystis jirovecii</i> | 8 (10) | 1 (2) | 1 (3) | 10 (6.3) |
| <i>Moraxella catarrhalis</i> | 3 (4) | 4 (9) | 1 (3) | 8 (5.0) |
| <i>Salmonella</i> species | 5 (6) | 1 (2) | 2 (5) | 8 (5.0) |
| <i>Bordetella pertussis</i> | 3 (4) | 3 (7) | 1 (3) | 7 (4.4) |
| <i>Haemophilus influenzae</i> non-type b | 2 (3) | 3 (7) | 1 (3) | 6 (3.8) |
| <i>Chlamydia pneumoniae</i> | 0 (0) | 2 (5) | 1 (3) | 3 (1.9) |
| <i>Mycoplasma pneumoniae</i> | 1 (1) | 0 (0) | 1 (3) | 2 (1.3) |
| Bocavirus | 7 (9) | 1 (2) | 3 (8) | 11 (6.9) |
| Parainfluenza 1 | 3 (4) | 3 (7) | 2 (5) | 8 (5.0) |
| Influenza C | 2 (3) | 3 (7) | 2 (5) | 7 (4.4) |
| Cytomegalovirus | 4 (5) | 2 (5) | 0 (0) | 6 (3.8) |
| Coronavirus HKU1 | 2 (3) | 0 (0) | 2 (5) | 4 (2.5) |
| Coronavirus 43 | 0 (0) | 4 (9) | 0 (0) | 4 (2.5) |
| Respiratory syncytial virus | 2 (3) | 1 (2) | 0 (0) | 3 (1.9) |
| Influenza A | 2 (3) | 0 (0) | 0 (0) | 2 (1.3) |
| Influenza B | 1 (1) | 0 (0) | 1 (3) | 2 (1.3) |
| Rhinovirus | 1 (1) | 0 (0) | 1 (3) | 2 (1.3) |
| Adenovirus | 1 (1) | 1 (2) | 0 (0) | 2 (1.3) |
| Human metapneumovirus | 2 (3) | 0 (0) | 0 (0) | 2 (1.3) |
| Pathogen(s) isolated | | | | |
| Any pathogen | 52 (68) | 35 (81) | 29 (73) | 116 (72.5) |
| No pathogen | 25 (32) | 8 (19) | 11 (27) | 44 (27.5) |
| 1 pathogen | 25 (32) | 16 (37) | 20 (50) | 61 (38.1) |
| 2 pathogens | 14 (18) | 14 (33) | 5 (10) | 33 (20.6) |
| 3 pathogens | 9 (12) | 1 (2) | 3 (8) | 13 (8.1) |
| 4 or more pathogens | 4 (5) | 4 (9) | 1 (3) | 9 (5.6) |
| Bacterial pathogen(s) | 43 (56) | 30 (70) | 24 (60) | 97 (60.6) |

| | | | | |
|----------------------------|---------|---------|---------|-----------|
| Bacterial pathogen(s) only | 30 (39) | 20 (47) | 17 (43) | 67 (41.9) |
| Viral pathogen(s) | 23 (30) | 15 (35) | 11 (28) | 49 (30.6) |
| Viral pathogen(s) only | 9 (12) | 5 (12) | 4 (10) | 18 (11.3) |

Co-infections isolated

| | | | | |
|----------------------------------|---------|---------|--------|-----------|
| Bacterial-bacterial co-detection | 11 (14) | 9 (21) | 6 (15) | 26 (16.3) |
| Bacterial-viral co-detection | 13 (17) | 10 (23) | 7 (18) | 30 (18.8) |
| Viral-viral co-detection | 6 (6) | 2 (5) | 0 (0) | 7 (4.4) |

212 Note: *H. influenzae* non-type b if *H. influenzae* target positive and Hib target negative; Hib if both targets
 213 positive.

214

215

216 The most frequent pathogens by multiplex PCR in lung specimens were *S. pneumoniae* (n=68, 43%), *S.*
 217 *aureus* (n=26, 16%), Hib (n=11, 7%), bocavirus (n=11, 7%), influenza viruses (n=11, 7%), *Pneumocystis*
 218 *jirovecii* (n=10, 6%), *Moraxella catarrhalis* (n=8, 5%), *Salmonella* sp. (n=8, 5%), and parainfluenza virus 1
 219 (n=8, 5%) [table 2]. Respiratory syncytial virus (RSV) was detected in only three specimens. *S. pneumoniae*
 220 was more prevalent in patients aged ≥ 2 years (42/83, 51%) compared to children aged 0-23 months (26/77,
 221 34%), odds ratio (OR) 2.01 (95% CI 1.01, 4.01). In contrast, *S. aureus* was more common in children aged <5
 222 years (22/120, 18%) compared to older children and adults (4/40, 10%), OR 2.02 (95% CI 0.62, 8.58). Hib
 223 was restricted to children aged <5 years. *P. jirovecii* was more common in children aged 0-23 months (8/77,
 224 10%) compared to patients aged ≥ 5 years (2/83, 2%), OR 4.75 (95% CI 0.90, 47.0).

225

226 Co-infection by pairs of pathogens is shown in table 3. *M. catarrhalis* was detected in eight patients and in
 227 every case there was co-infection with *S. pneumoniae* (8/68 with *S. pneumoniae* versus 0/92 without *S.*
 228 *pneumoniae*, $p=0.0007$). *B. pertussis* was detected in seven patients and in six there was co-infection with *S.*
 229 *pneumoniae* (6/68 with *S. pneumoniae* versus 1/92 without *S. pneumoniae*, $p=0.018$). These comparisons
 230 are subject to multiple testing of 54 pairs of pathogens.

Table 3. Frequency of detection of pairs of pathogens identified by multiplex PCR assay in 156 lung and 4 pleural aspirate specimens

| Pathogen | <i>S. pneumoniae</i> | <i>S. aureus</i> | ^a Hib | <i>P. jirovecii</i> | <i>M. catarrhalis</i> | <i>Salmonella</i> | <i>B. pertussis</i> | ^b Hi non-b | Bocavirus | ^c Influenza | Parainfluenza 1 |
|-----------------------|----------------------|------------------|------------------|---------------------|-----------------------|-------------------|---------------------|-----------------------|-----------|------------------------|-----------------|
| <i>S. pneumoniae</i> | 68 | | | | | | | | | | |
| <i>S. aureus</i> | 13 | 26 | | | | | | | | | |
| Hib | 3 | 2 | 11 | | | | | | | | |
| <i>P. jirovecii</i> | 5 | 1 | 0 | 10 | | | | | | | |
| <i>M. catarrhalis</i> | 8 | 4 | 2 | 0 | 8 | | | | | | |
| <i>Salmonella</i> | 5 | 3 | 1 | 2 | 1 | 8 | | | | | |
| <i>B. pertussis</i> | 6 | 3 | 0 | 1 | 2 | 2 | 7 | | | | |
| Hi non-b | 4 | 1 | ND | 1 | 2 | 0 | 0 | 6 | | | |
| Bocavirus | 6 | 2 | 0 | 1 | 1 | 2 | 0 | 1 | 11 | | |
| Influenza | 5 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 0 | 11 | |
| Parainfluenza 1 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 8 |

^aHib – *H. influenzae* type b; ^bHi non-b – non-type b *H. influenzae*; ^cInfluenza – Influenza A, B, C.

Using lung aspirate PCR results, the proportion of children aged 2-59 months hospitalized with clinical pneumonia in whom *S. pneumoniae* was detected was lower among those who had received ≥ 2 doses of PCV compared to zero doses (table 4); age stratified OR 0.42 (95% CI 0.16, 1.05). Using a combination of culture and lung specimen PCR results, the proportion in whom *S. pneumoniae* was detected was less among those who had received ≥ 2 doses of PCV compared to zero doses (Supplementary Table 2); age-stratified OR 0.54 (95% CI 0.33, 0.90). Using culture and serotyping results, the proportion of children in whom vaccine-type pneumococci were isolated was significantly less among those who had received ≥ 2 doses of PCV compared to zero doses (table 4); age-stratified OR 0.17 (95% CI 0.06, 0.51).

Table 4. Association of pneumococcal pneumonia with PCV vaccination status

| Pneumonia aetiology by PCR on lung/pleural aspirate | Number of PCV doses (PCV7 or PCV13) | | Total N | Odds ratio (95% CI) |
|---|-------------------------------------|---------|---------|---------------------|
| | ≥ 2 doses | 0 doses | | |
| Age 2-11 months | N=27 | N=11 | | |
| PCR pneumococcal | 4 | 4 | 8 | |
| PCR not pneumococcal | 23 | 7 | 30 | 0.30 (0.04, 2.16) |
| Proportion PCR pneumococcal | 0.15 | 0.36 | 38 | |
| Age 12-23 months | N=26 | N=3 | | |
| PCR pneumococcal | 12 | 2 | 14 | |
| PCR not pneumococcal | 14 | 1 | 15 | 0.43 (0.007, 9.5) |
| Proportion PCR pneumococcal | 0.46 | 0.66 | 29 | |
| Age 2-4 years | N=18 | N=23 | | |
| PCR pneumococcal | 7 | 13 | 20 | |
| PCR not pneumococcal | 11 | 10 | 21 | 0.49 (0.12, 2.03) |
| Proportion PCR pneumococcal | 0.39 | 0.57 | 41 | |
| Combined age strata 2-59 months, ^a M-H age-stratified odds ratio = 0.42 (0.16, 1.05), ^b p=0.062 | | | | |
| Pneumonia aetiology by culture of blood or lung/pleural aspirate and pneumococcal serotyping | | | | |
| Age 2-11 months | N=540 | N=184 | | |
| ^v Vaccine-type pneumococcal | 1 | 1 | 2 | |

| | | | | |
|--|-------|-------|-----|--------------------|
| Not vaccine-type pneumococcal | 539 | 183 | 722 | 0.34 (0.004, 26.8) |
| Proportion vaccine-type pneumococcal | 0.002 | 0.005 | 700 | |
| Age 12-23 months | N=515 | N=81 | | |
| ^c Vaccine-type pneumococcal | 3 | 2 | 5 | |
| Not vaccine-type pneumococcal | 512 | 79 | 591 | 0.23 (0.03, 2.82) |
| Proportion vaccine-type pneumococcal | 0.006 | 0.025 | 596 | |
| Age 2-4 years | N=230 | N=218 | | |
| ^c Vaccine-type pneumococcal | 2 | 13 | 15 | |
| Not vaccine-type pneumococcal | 228 | 205 | 427 | 0.14 (0.02, 0.62) |
| Proportion vaccine-type pneumococcal | 0.009 | 0.059 | 441 | |
| Combined age strata 2-59 months, ^a M-H age-stratified odds ratio = 0.17 (0.06, 0.51), ^b p=0.0005 | | | | |

^aMantel-Haenzel age-stratified odds ratio. ^bFisher's exact *p*-value. ^cVaccine-type defined as PCV7 serotypes for children who received PCV7, and PCV13 serotypes for children who received PCV13 or a combination of PCV7 and PCV13.

The greatest pathogen load in lung specimens was associated with *S. pneumoniae* (median 5.34 [IQR 3.73, 6.24] log₁₀ copies/ml), *H. influenzae* non-type b (median 6.07 [IQR 5.32, 6.86] log₁₀ copies/ml) and parainfluenza virus (PIV) 1 (median 6.46 [IQR 4.74, 10.93] log₁₀ copies/ml) positive specimens (Supplementary Table 1). Low pathogen load was associated with *S. aureus* (median 2.15 [IQR 1.68, 4.14] log₁₀ copies/ml), bocavirus (median 2.77 [IQR 2.19, 3.40] log₁₀ copies/ml), and cytomegalovirus (2.57 [IQR 2.38, 3.71] log₁₀ copies/ml) positive specimens.

DISCUSSION

We have investigated the aetiology of lobar pneumonia in rural West Africa by applying multiplex molecular methods to a large number of lung specimens. Pathogens were detected in 73% of specimens with bacteria predominant. *S. pneumoniae* (43%) was the dominant pathogen followed by *S. aureus* (16%). Co-infection was common (34%) with bacterial-bacterial co-infection similar in prevalence to bacterial-viral co-infection. We observed correlated co-infection between *M. catarrhalis* and *S. pneumoniae*. The estimated effectiveness of ≥ 2 doses of PCV to prevent vaccine-type pneumococcal pneumonia was 83% (95% CI 49%, 94%). We have shown previously the association of the pneumococcus with severe lobar pneumonia in the study area.^{13:20} Despite a well-established vaccination program, Hib was aetiologic in 9% of lobar pneumonia in young children. These cases may relate to disease before the age of immunization, delayed vaccine administration, waning immunity or unvaccinated migrants, but also continued transmission despite over 91% coverage of the three-dose schedule.²¹ Although ongoing cases of culture-positive invasive Hib disease are documented in The Gambia²¹, it is only our attention to non-bacteraemic pneumonia that revealed this type of residual Hib disease.

The finding of *S. aureus* aetiology in 18% of lobar pneumonia cases in young children is of concern given that empiric therapy for severe pneumonia in our setting is penicillin/ampicillin and gentamicin,²² which has sub-optimal activity against staphylococcus. Ceftriaxone is recommended for severely ill children with hypoxia, heart failure, or who are unable to feed. Cloxacillin is recommended if no improvement in 48 hours or staphylococcal pneumonia is suspected.²² Unfortunately, clinical features indicative of staphylococcal pneumonia are not reliable and radiology and microbiology are not generally available. The finding of *P. jirovecii* in 10% of lobar pneumonia in 0-23 month-olds was surprising as HIV prevalence is low in our setting. This relatively high prevalence may relate to undiagnosed HIV, HIV exposure, malnutrition, or be related to chance with small numbers of cases (n=10). Additional data are needed before a recommendation for HIV

testing in children with lobar pneumonia is considered in this setting. We found *M. catarrhalis*, *Salmonella* sp., *B. pertussis*, and non-type b *H. influenzae* etiologic in 4-5% of cases of lobar pneumonia.

We did not expect to find bocavirus as the most prevalent virus associated with lobar pneumonia (11/160), although our data are consistent with parainfluenza and influenza viruses causing severe lower respiratory infections. The PERCH study found RSV to be the virus most associated with severe pneumonia, and bocavirus as the 7th most associated virus.² However, bocavirus is a documented cause of pneumonia in The Gambia⁹ and South Africa.⁴ The single-site nature of our study and multi-country PERCH data, or temporal transmission during the period of our study, may explain the differences in the prevalence of bocavirus and RSV. Alternatively, differing mechanisms of disease may explain our low prevalence of RSV, causing primarily upper respiratory and bronchiolar infection without alveolar consolidation, and bocavirus causing parenchymal disease.

Our finding that bacteria dominate the aetiology of lobar pneumonia aligns with both historical studies using lung aspirates^{5;7;8;23} and recent studies using lung aspirates and molecular detection methods.^{2;9} A Gambian study from 2007-2009 investigated 53 lung and pleural aspirates and found *S. pneumoniae* in 48, *H. influenzae* in 12, *S. aureus* and *Acinetobacter* sp. in three each and only one virus only infection. RSV, adenovirus, and bocavirus were detected in co-infection in two cases each.⁹ PERCH data from 2012-2013, in which PCR detected pathogens in 43% of 37 lung and 15 pleural aspirates, detected pneumococcus in 13 specimens, *S. aureus* in seven, Hib in four, *M. catarrhalis* in four, viruses in three, and no RSV.²

Our observation of co-infection with two (21%), three (8%), and four or more pathogens (6%) underscores the polymicrobial nature of lobar pneumonia. Bacterial-bacterial and bacterial-viral co-infections were of similar prevalence. In the setting of co-infection, the estimation of aetiological

proportions due to individual pathogens remains a challenge with all aetiological pathogens necessarily contributing to more than 100% of cases. The importance of co-infections, temporal pathogenesis, and the interplay of viral upper and bacterial lower respiratory infections, raises the potential for vaccine interventions to impact pathogenesis involving non-target pathogens. The synergistic role of *S. pneumoniae* has already been demonstrated in a vaccine probe study showing the administration of PCV prevented hospitalization with viral-associated lower respiratory disease.²⁴

The correlation we observed between *M. catarrhalis* and *S. pneumoniae* is intriguing. This may be explained by true synergism or by correlation alone given these organisms commonly co-colonize the upper respiratory tract. Aspiration of upper respiratory flora in the pathogenesis of lobar pneumonia would result in co-detection of such bacteria in lung tissue, if bacteria were able to avoid neutrophil killing and other clearance mechanisms.

We estimated the effectiveness of PCV against non-bacteraemic pneumococcal pneumonia, which has not been possible in most trials. Among adults in the Netherlands the efficacy of one dose of PCV13 was 45% (95% CI 14%, 65%) to prevent non-invasive vaccine-type pneumococcal pneumonia and 75% (95% CI 41%, 91%) to prevent vaccine-type invasive disease. Our estimates of PCV effectiveness against vaccine-type (OR 0.17; 95% CI 0.06, 0.51) and all pneumococcal pneumonia (OR 0.42; 95% CI 0.16, 1.05) are similar to the Gambian PCV9 trial estimates of efficacy against lung aspirate positive vaccine-type (73%) and all pneumococcal pneumonia (68%).²⁵

The main strength of our study is the inclusion of a significant number of lung aspirate specimens combined with a sensitive and specific multiplex PCR assay. Our study was limited by the range of potential pathogens detected and sample size. The multiplex assay excluded measles and *M. tuberculosis*. The PERCH study found no cases of *M. tuberculosis* in lung or pleural aspirates but it

was isolated in The Gambia in 7/255 induced sputum specimens.² The already cited Gambian study of 53 lung specimens found no cases of *M. tuberculosis*.⁹ Our analyses excluded *Legionella* and *Klebsiella* sp. due to poor assay specificity. Our cross-sectional design was not able to investigate the temporal aspects of pneumonia pathogenesis. The limited duration of our study may also introduce potential bias due to variation in the seasonal transmission of individual pathogens.

Understanding the contribution of less prevalent pathogens in lobar pneumonia, the age distribution of pathogen aetiology, and questions concerning co-infection and synergism will require larger sample sizes. More sensitive and specific multiplex assays may identify additional pathogens. Studies of pneumonia aetiology, and childhood pneumonia in general, should carefully consider the use of specific case definitions, for example separating bronchiolitis and lobar pneumonia phenotypes, to avoid heterogeneity in outcome measurements.²⁶ Longitudinal studies of pneumonia pathogenesis, or vaccine probe studies (such as with an RSV vaccine), may help determine the relationships between viruses and bacteria. Studies of pathogen gene expression in the lung²⁷ may reveal new therapeutic approaches.

Our study provides important information concerning the aetiology of lobar pneumonia in a setting with significant child mortality during the period of introduction of PCV. Our findings may not be generalizable to settings with different levels of vaccine coverage and nasopharyngeal bacterial carriage. Further studies using lung aspirates will address a number of remaining important questions.

Author affiliations

See title page.

Acknowledgements

We are grateful to the staff at Basse District Hospital and Bansang Hospital and staff of the Pneumococcal Surveillance Project who provided clinical evaluation and care for the patients. The Regional Health Teams in Upper and Central River Region provided logistic support.

Contributors

GM conceived and designed the study, conducted the analysis, and wrote the first draft of the manuscript. JM and EM conducted multiplex qPCR analyses and reviewed the manuscript. MN, JP, AF, BA, and IH enrolled the patients, collected the specimens and reviewed the manuscript. AM conducted conventional microbiological analyses and reviewed the manuscript. BG and PH advised on analysis and reviewed the manuscript. All authors approved the final version of the manuscript for submission.

Funding

This work was supported by the Bill & Melinda Gates Foundation [grant number OPP1020327] and the Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine.

Competing interests

The authors declare no competing interests.

Patient consent for publication

Not required.

Ethics approval

Ethical approval was granted for the study by the Gambia Government/Medical Research Council (UK) Joint Ethics Committee (numbers 1087 and 1247). Written informed consent was obtained from patients or guardian for all study procedures.

Provenance and peer review

Not commissioned, externally peer reviewed. No part of this work has been written by a medical writer. Some of the findings of this study were presented at the 66th annual meeting of the American Society of Tropical Medicine & Hygiene (abstract #: 17-A-1389).

Data availability statement

Data are available upon reasonable request to the MRCG Scientific Coordinating Committee and Gambia Government/MRCG Joint Ethics Committee. Deidentified patient data may be requested from the MRCG Data Management and Archives department.

Figure legends

Figure 1. Study profile

References

- (1) Selwyn BJ. The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Coordinated Data Group of BOSTID Researchers. *Rev Infect Dis* 1990;12:S870-88.
- (2) PERCH Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. *Lancet* 2019;394:757-79.
- (3) Benet T, Sanchez P, V, Messaoudi M, *et al.* Microorganisms Associated With Pneumonia in Children <5 Years of Age in Developing and Emerging Countries: The GABRIEL Pneumonia Multicenter, Prospective, Case-Control Study. *Clin Infect Dis* 2017;65:604-12.
- (4) Zar HJ, Barnett W, Stadler A, Gardner-Lubbe S, Myer L, Nicol MP. Aetiology of childhood pneumonia in a well vaccinated South African birth cohort: a nested case-control study of the Drakenstein Child Health Study. *Lancet Respir Med* 2016;4:463-72.
- (5) Shann F, Gratten M, Germer S, Linnemann V, Hazlett D, Payne R. Aetiology of pneumonia in children in Goroka Hospital, Papua New Guinea. *Lancet* 1984;2:537-41.
- (6) Kalra SK, Sasidharan T, Vatwani V, Sarkar P. Lung puncture: a diagnostic aid in childhood pneumonia. *Indian Pediatr* 1981;18:727-30.
- (7) Wall RA, Corrah PT, Mabey DC, Greenwood BM. The etiology of lobar pneumonia in the Gambia. *Bull World Health Organ* 1986;64:553-8.
- (8) Silverman M, Stratton D, Diallo A, Egler LJ. Diagnosis of acute bacterial pneumonia in Nigerian children. Value of needle aspiration of lung. *Arch Dis Child* 1977;52:925-31.
- (9) Howie SR, Morris GA, Tokarz R, *et al.* Etiology of severe childhood pneumonia in the Gambia, West Africa, determined by conventional and molecular microbiological analyses of lung and pleural aspirate samples. *Clin Infect Dis* 2014;59:682-5.
- (10) Duke T. What the PERCH study means for future pneumonia strategies. *Lancet* 2019;394:714-6.
- (11) Mackenzie GA, Plumb ID, Sambou S, *et al.* Monitoring the introduction of pneumococcal conjugate vaccines into West Africa: design and implementation of a population-based surveillance system. *PLoS Med* 2012;9:e1001161.
- (12) Mackenzie GA, Hill PC, Jeffries DJ, *et al.* Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. *Lancet Infect Dis* 2016;16:703-11.
- (13) Mackenzie GA, Hill PC, Sahito SM, *et al.* Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies. *Lancet Infect Dis* 2017;17:965-73.
- (14) National AIDS Control Programme. Republic of The Gambia, HIV Sentinel Surveillance Report 2011. Banjul: Ministry of Health & Social Welfare; 2012.

- (15) World Health Organization Pneumonia Vaccine Trial Investigators' Group. Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. World Health Organization, Department of Vaccines and Biologicals. 2001. Available at: <http://www.who.int/vaccines-documents>. Accessed 5 October 2004.
- (16) Ideh RC, Howie SR, Ebruke B, *et al.* Transthoracic lung aspiration for the aetiological diagnosis of pneumonia: 25 years of experience from The Gambia. *Int J Tuberc Lung Dis* 2011;15:729-35.
- (17) Adegbola RA, Falade AG, Sam BE, *et al.* The etiology of pneumonia in malnourished and well-nourished Gambian children. *Pediatr Infect Dis J* 1994;13:975-82.
- (18) O'Neill KP, Lloyd-Evans N, Campbell H, Forgie IM, Sabally S, Greenwood BM. Latex agglutination test for diagnosing pneumococcal pneumonia in children in developing countries. *BMJ* 1989;298:1061-4.
- (19) Driscoll AJ, Karron RA, Morpeth SC, *et al.* Standardization of Laboratory Methods for the PERCH Study. *Clin Infect Dis* 2017;64:S245-S252.
- (20) Mackenzie GA, Hill PC, Jeffries DJ, *et al.* Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance. *Lancet Infect Dis* 2021 [in press].
- (21) Zaman SM, Howie SR, Ochoge M, *et al.* Impact of routine vaccination against Haemophilus influenzae type b in The Gambia: 20 years after its introduction. *J Glob Health* 2020;10:010416.
- (22) Ministry of Health. Standard Treatment Guidelines. The Gambia: Ministry of Health; 2017.
- (23) Diakparomre MA, Obi JO. Aetiological diagnosis of pneumonia in childhood by lung puncture. *Nigerian J of Paediatrics* 1981;8:61-4.
- (24) Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. *Nat Med* 2004;10:811-3.
- (25) Cutts FT, Zaman SM, Enwere G, *et al.* Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. *Lancet* 2005;365:1139-46.
- (26) Mackenzie G. The definition and classification of pneumonia. *Pneumonia* 2016;8:14.
- (27) Dunne EM, Hua Y, Salaudeen R, *et al.* Insights into pneumococcal pneumonia using lung aspirates and nasopharyngeal swabs collected from pneumonia patients in The Gambia. *J Infect Dis* 2020; doi 10.1093/infdis/jjaa186.

Figure 1. Study profile

